Gino Santini - Net Worth and Insider Trading

Gino Santini Net Worth

The estimated net worth of Gino Santini is at least $84 Million dollars as of 2025-04-25. Gino Santini is the Sr.VP, Corp. Strategy & Policy of Eli Lilly and Co and owns about 89,010 shares of Eli Lilly and Co (LLY) stock worth over $77 Million. Gino Santini is also the Director of Horizon Therapeutics PLC and owns about 63,303 shares of Horizon Therapeutics PLC (HZNP) stock worth over $7 Million. Details can be seen in Gino Santini's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Gino Santini has not made any transactions after 2021-03-01 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Gino Santini

Gino Santini Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Gino Santini owns 7 companies in total, including Horizon Therapeutics PLC (HZNP) , AMAG Pharmaceuticals Inc (AMAG) , and Intercept Pharmaceuticals Inc (ICPT) among others .

Click here to see the complete history of Gino Santini’s form 4 insider trades.

Insider Ownership Summary of Gino Santini

Ticker	Company	Transaction Date	Type of Owner
HZNP	Horizon Therapeutics PLC	2021-03-01	director
AMAG	AMAG Pharmaceuticals Inc	2020-06-02	director
ICPT	Intercept Pharmaceuticals Inc	2020-05-28	director
		2022-05-19	director
		2017-11-01	director
		2016-10-25	director
		2005-12-15	President & US Operations

Gino Santini Latest Holdings Summary

Gino Santini currently owns a total of 2 stocks. Among these stocks, Gino Santini owns 89,010 shares of Eli Lilly and Co (LLY) as of December 15, 2005, with a value of $77 Million and a weighting of 91.22%. Gino Santini also owns 63,303 shares of Horizon Therapeutics PLC (HZNP) as of March 1, 2021, with a value of $7 Million and a weighting of 8.78%.

Latest Holdings of Gino Santini

Ticker	Company	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
LLY	Eli Lilly and Co	2005-12-15	89,010	859.73	76,524,567
HZNP	Horizon Therapeutics PLC	2021-03-01	63,303	116.30	7,362,139

Holding Weightings of Gino Santini

Gino Santini Form 4 Trading Tracker

According to the SEC Form 4 filings, Gino Santini has made a total of 0 transactions in Eli Lilly and Co (LLY) over the past 5 years. The most-recent trade in Eli Lilly and Co is the sale of 5,000 shares on December 15, 2005, which brought Gino Santini around $280,700.

According to the SEC Form 4 filings, Gino Santini has made a total of 1 transactions in Horizon Therapeutics PLC (HZNP) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Horizon Therapeutics PLC is the sale of 12,000 shares on March 1, 2021, which brought Gino Santini around $1 Million.

Insider Trading History of Gino Santini

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Gino Santini Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Gino Santini Ownership Network

Ownership Network List of Gino Santini

No Data

Ownership Network Relation of Gino Santini

Gino Santini Owned Company Details

What does Horizon Therapeutics PLC do?

Who are the key executives at Horizon Therapeutics PLC?

Gino Santini is the director of Horizon Therapeutics PLC. Other key executives at Horizon Therapeutics PLC include EVP and Chief Business Officer Andy Pasternak , EVP & Chief Financial Officer Aaron Cox , and EVP & Chief Medical Officer Jeffrey W Sherman .

Horizon Therapeutics PLC (HZNP) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Horizon Therapeutics PLC (HZNP) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Horizon Therapeutics PLC (HZNP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Horizon Therapeutics PLC (HZNP)'s detailed insider trading history can be found in Insider Trading Tracker table.

Horizon Therapeutics PLC Insider Transactions

No Available Data

What does AMAG Pharmaceuticals Inc do?

Who are the key executives at AMAG Pharmaceuticals Inc?

Gino Santini is the director of AMAG Pharmaceuticals Inc. Other key executives at AMAG Pharmaceuticals Inc include 10 percent owner Camber Capital Management Lp , Chief Operating Officer Anthony Casciano , and Interim CFO Brian Piekos .

AMAG Pharmaceuticals Inc (AMAG) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of AMAG Pharmaceuticals Inc (AMAG) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of AMAG Pharmaceuticals Inc (AMAG) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

AMAG Pharmaceuticals Inc (AMAG)'s detailed insider trading history can be found in Insider Trading Tracker table.

AMAG Pharmaceuticals Inc Insider Transactions

No Available Data

What does Intercept Pharmaceuticals Inc do?

Who are the key executives at Intercept Pharmaceuticals Inc?

Gino Santini is the director of Intercept Pharmaceuticals Inc. Other key executives at Intercept Pharmaceuticals Inc include EVP & Chief Financial Officer Andrew Saik , President & R&D and CMO M Michelle Berrey , and Chief Accounting Officer Rocco Venezia .

Intercept Pharmaceuticals Inc (ICPT) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Intercept Pharmaceuticals Inc (ICPT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Intercept Pharmaceuticals Inc (ICPT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Intercept Pharmaceuticals Inc (ICPT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Intercept Pharmaceuticals Inc Insider Transactions

No Available Data

What does Collegium Pharmaceutical Inc do?

Who are the key executives at Collegium Pharmaceutical Inc?

Gino Santini is the director of Collegium Pharmaceutical Inc. Other key executives at Collegium Pharmaceutical Inc include EVP & Chief Financial Officer Tupper Colleen , EVP & Chief Commercial Officer Scott Dreyer , and EVP and General Counsel Shirley R. Kuhlmann .

Collegium Pharmaceutical Inc (COLL) Insider Trades Summary

Over the past 18 months, Gino Santini made no insider transaction in Collegium Pharmaceutical Inc (COLL). Other recent insider transactions involving Collegium Pharmaceutical Inc (COLL) include a net sale of 201,056 shares made by Scott Dreyer , a net sale of 184,392 shares made by Shirley R. Kuhlmann , and a net sale of 42,187 shares made by Tupper Colleen .

In summary, during the past 3 months, insiders sold 168,024 shares of Collegium Pharmaceutical Inc (COLL) in total and bought 0 shares, with a net sale of 168,024 shares. During the past 18 months, 539,338 shares of Collegium Pharmaceutical Inc (COLL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 539,338 shares.

Collegium Pharmaceutical Inc (COLL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Collegium Pharmaceutical Inc Insider Transactions

No Available Data

What does Allena Pharmaceuticals Inc do?

Who are the key executives at Allena Pharmaceuticals Inc?

Gino Santini is the director of Allena Pharmaceuticals Inc. Other key executives at Allena Pharmaceuticals Inc include See Remarks Louis Md Brenner , Chief Financial Officer Richard D Katz , and Chief Financial Officer Edward Wholihan .

Allena Pharmaceuticals Inc (ALNAQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Allena Pharmaceuticals Inc (ALNAQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Allena Pharmaceuticals Inc (ALNAQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Allena Pharmaceuticals Inc (ALNAQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Allena Pharmaceuticals Inc Insider Transactions

No Available Data

What does Vitae Pharmaceuticals Inc do?

Who are the key executives at Vitae Pharmaceuticals Inc?

Gino Santini is the director of Vitae Pharmaceuticals Inc. Other key executives at Vitae Pharmaceuticals Inc include Chief Financial Officer Richard Steven Morris , General Counsel Scott Applebaum , and Chief Medical Officer Carole Sable .

Vitae Pharmaceuticals Inc (VTAE) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Vitae Pharmaceuticals Inc (VTAE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Vitae Pharmaceuticals Inc (VTAE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Vitae Pharmaceuticals Inc (VTAE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Vitae Pharmaceuticals Inc Insider Transactions

No Available Data

What does Eli Lilly and Co do?

Who are the key executives at Eli Lilly and Co?

Gino Santini is the President & US Operations of Eli Lilly and Co. Other key executives at Eli Lilly and Co include Chief Accounting Officer Donald A Zakrowski , 10 percent owner Lilly Endowment Inc , and SVP & CSO & and Pres. LRL Daniel Skovronsky .

Eli Lilly and Co (LLY) Insider Trades Summary

Over the past 18 months, Gino Santini made no insider transaction in Eli Lilly and Co (LLY). Other recent insider transactions involving Eli Lilly and Co (LLY) include a net sale of 3,505,933 shares made by Lilly Endowment Inc , a net sale of 4,820 shares made by Donald A Zakrowski , and a net sale of 7,056 shares made by Johna Norton .

In summary, during the past 3 months, insiders sold 881,000 shares of Eli Lilly and Co (LLY) in total and bought 0 shares, with a net sale of 881,000 shares. During the past 18 months, 3,522,809 shares of Eli Lilly and Co (LLY) were sold and 0 shares were bought by its insiders, resulting in a net sale of 3,522,809 shares.

Eli Lilly and Co (LLY)'s detailed insider trading history can be found in Insider Trading Tracker table.

Eli Lilly and Co Insider Transactions

No Available Data

Gino Santini Mailing Address

Above is the net worth, insider trading, and ownership report for Gino Santini. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Gino Santini's mailing address is: Waltham Ma 02451.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.